PAVmed

PAVM

Medical - Devices · Healthcare

Price

$5.92

-0.10 (-1.58%)

Market Cap

$3.2M

Exchange

NASDAQ Capital Market

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Share count rising — dilution

+289.2% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 172K (2021) → 670K (2025)

PAVmed Inc. is a small medical technology company that develops and commercializes medical devices and digital health products. Its main focus is on two areas: a subsidiary called Lucid Diagnostics, which makes a test called EsoGuard that screens for a condition that can lead to esophageal cancer, and PortIO, a device designed to provide long-term access to a patient's bloodstream. Its customers are primarily hospitals, clinics, and physicians in the United States.

PAVmed makes money by selling diagnostic tests and medical devices, though it is still in an early stage and spends far more than it earns. The company operates mainly in the United States and has a very small market presence. Its negative gross and operating margins show it is not yet profitable and relies on outside funding to keep running. The biggest risk the company faces is running out of cash before its products gain enough commercial traction to generate meaningful revenue.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+175.0% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

-111.6% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$4.5B/ year

↑ Rising (+75625% vs prior year)

>1,000% of revenue

351486.7x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

17.9%ownership

Insiders own a meaningful stake in the company

Cash Runway

~0 months

$42M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Revenue accelerating

PAVmed grew revenue 175% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

-431.8%

Thin — -431.8% gross margin

Operating Margin

-36522.7%

Losing money on operations — -36522.7%

ROCE

-14.6%

Weak — -14.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-95.7%

Shrinking sales (-95.7% YoY)

EPS YoY

-118.9%

Earnings shrinking (-118.9% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

-3086672.9%

Burning cash (-3086672.9%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.39

Conservative — low debt load (0.39)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial